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Highlights: 
 
Headspace NTD sampling to determine VOCs in whole blood is studied. 
 
Matrix effect is very significant in complex biological matrices such as blood. 
 
LODs at ng·L-1 are easily achieved by concentration with active HS-NTD sampling. 
 
HS-NTD is a robust, sensitive and simple methodology for VOC analysis. 
 
*Highlights (for review)
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Abstract18
Needle trap devices (NTDs) are a relatively new and promising tool for headspace (HS) 19
analysis. In this study, a dynamic HS sampling procedure is evaluated for the 20
determination of volatile organic compounds (VOCs) in whole blood samples. A full 21
factorial design was used to evaluate the influence of the number of cycles and 22
incubation time and it is demonstrated that the controlling factor in the process is the 23
number of cycles. A mathematical model can be used to determine the most appropriate 24
number of cycles required to adsorb a prefixed amount of VOCs present in the HS 25
phase whenever quantitative adsorption is reached in each cycle. Matrix effect is of 26
great importance when complex biological samples, such as blood, are analyzed. The 27
evaluation of the salting out effect showed a significant improvement in the 28
volatilization of VOCs to the HS in this type of matrices. Moreover, a 1:4 (blood:water) 29
dilution is required to obtain quantitative recoveries of the target analytes when external 30
calibration is used. The method developed gives detection limits in the 0.020-0.08031
g·L-1 range (0.1-0.4 g·L-1 range for undiluted blood samples) with appropriate 32
repeatability values (RSD<15% at high level and <23% at LOQ level). Figure of merits 33
of the method can be improved by using a smaller phase ratio (i.e., an increase in the 34
blood volume and a decrease in the HS volume), which lead to lower detection limits, 35
better repeatability values and greater sensibility. Twenty-eight blood samples have 36
been evaluated with the proposed method and the results agree with those indicated in 37
other studies. Benzene was the only target compound that gave significant differences 38
between blood levels detected in volunteer non-smokers and smokers.39
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1. Introduction43
Volatile organic compounds (VOCs) are a group of contaminants of great interest as 44
they are encountered in the workplace, in daily routines, widely used consumer 45
products, and are ubiquitous in both outdoor and indoor air. Inhalation of VOCs is the 46
most common route of exposure [1,2], but they can also be absorbed through the skin47
[3-5] and, in some cases, oral uptake may be of considerable importance [6]. In order to 48
evaluate the individual exposure of a person to VOCs and the resulting health risk, it is 49
necessary to determine the internal exposure by analyzing biological fluids. Different 50
occupational studies have revealed that levels of VOCs and their metabolites in blood 51
tend to correlate highly with the corresponding air levels [7].52
In normal healthy subjects many VOCs are detected in blood at very small 53
concentrations (tens to hundreds of ng·L-1) [8-13], except acetone (few mg·L-1) [8].54
Measuring such low levels in human biological fluids accurately and reproducibly 55
presents a complex analytical problem that requires special techniques and great care 56
[14,15]. In forensic analytical toxicology, the separation of organic compounds from 57
biological matrices is one of the most important and complex aspects of the entire 58
analytical procedure. Another difficulty observed is that some volatile substances are 59
present at concentrations below the detection limits of the available instrumentation60
[16].61
Headspace (HS) analysis is the most common technique for the determination of VOCs62
in biological fluids [17]. Conventional HS-GC is a routine technique for VOCs present 63
at higher concentrations in blood (mainly methanol and ethanol) [18-22], with LODs in 64
the 0.2-20 mg·L-1 range. The use of HS-GC with large volume collection from the 65
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headspace [23], sometimes with cryogenic oven trapping [24,25] and cryo-focussing 66
[26], has been used to improve sensitivity (LODs at ng·L-1 level). However, this 67
technique does not permit the evaluation of the presence of VOCs that can be used as 68
endogenous or exogenous markers.69
The determination of VOCs by purge-and-trap (PT) makes it possible to significantly70
reduce the LODs to the ng·L-1 level [8,9,12,27,28]. Unfortunately, PT-GC is not suitable 71
for blood samples as it results in foaming and the clogging up of the gas flow routes. 72
The use of an antifoam agent, added at a level that is high enough to prevent foaming, is 73
essential in the PT analysis of blood samples [15], but can lead to sample contamination 74
unless the antifoaming agent is heated under vacuum [8,29].75
The most common concentration technique for the determination of minority VOCs in 76
blood is solid-phase microextraction (SPME). HS-SPME allows LODs to be obtained at 77
ng·L-1 without the foaming problem [10,11,16,21,30-32].78
HS sampling is heavily dependent on the sample matrix and so results can vary79
significantly [19,20,33]. Blood is very complex and varies from one person to another, 80
and it has a strong matrix effect due to its rich protein content [19]. It is therefore 81
necessary to compensate the matrix effect in HS blood analysis to obtain reliable 82
quantitative results. A well-established and accepted method in forensic medicine for 83
this purpose is to use an internal standard (IS) based matrix-matched calibration method84
[19-22], although it has been found that the use of an IS in itself does not generally 85
eliminate the matrix effect and systematic errors may still occur [19,34].86
The dilution of blood with water is the simplest method to reduce matrix effects as it (i) 87
minimizes the effect of matrix proteins, which can bind analytes, and (ii) reduces the 88
matrix viscosity, which increases the diffusion coefficients, allowing greater extraction 89
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efficiency. The main drawback of dilution is that it leads to an increase in detection 90
limits. The most common dilution ratio used in blood analysis is 1:1 with water or an 91
aqueous solution of an IS [16-18,22-24,27]. Some authors have indicated that 1:1 92
dilution avoids matrix interference by endogenous compounds in blood [16,18].93
Unfortunately, there are no common criteria for the evaluation of the effect of dilution 94
on the matrix effect and some authors suggest greater dilution (e.g., 1:5 [21] and 1:2 95
[31]). On the other hand, in many other cases blood samples are analyzed directly 96
without dilution [8-11,26,28].97
In HS analysis, the addition of salts has a greater influence on the distribution of highly 98
hydrophilic components towards the gas phase than temperature [35]. Moreover, 99
compensation of the salting-out effect is essential in biological fluids where the ionic 100
strength, which influences solubility, may vary considerably from one sample to another101
[36]. In this situation, the added salt compensates for any ionic-strength effect. Houte et 102
al. [27] found a dramatic improvement in the recovery of VOCs when a salting-out 103
substance was used. Gottzein et al. [31] reported no influence of adding salts by SPME 104
analysis, but the amount of salt added was very small and was insufficient to 105
compensate for random salt concentrations in different biological samples. As in the 106
case of sample dilution, there are no agreed criteria for the salting-out effect. Some 107
studies have taken into account the salting-out effect [16,21,22,27] whereas others have 108
not [8-11,18-20,23,31].109
Another parameter to considerer in HS sampling is the temperature applied during the 110
equilibration of VOCs in the gas phase. Although the distribution coefficient of 111
hydrophilic compounds is favored at increased temperatures in HS, protein denaturation 112
takes place at T>43ºC. Therefore, HS temperatures below this value are recommended 113
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for VOC analysis in blood samples [16]. Higher temperatures can result in undesired 114
changes to the blood samples caused by thermal stress within the heated vial.115
It is necessary to develop simple and sensitive methods for managing difficult 116
biological matrices such as blood. In this study, we have evaluated the behavior of 117
needle trap devices (NTDs) for this purpose. This is a relatively new, simple and robust118
methodology that has shown promising results in the analysis of VOCs from aqueous 119
solutions [37]. Different effects (e.g., dilution and salting-out) have been evaluated in 120
order to find the best experimental conditions to obtain quantitative recoveries of all the121
target compounds.122
123
2. Experimental124
2.1. Materials125
Carboxen 1000 (60/80 mesh, specific surface area of 1200 m2·g-1 and a density of 0.47 126
g·mL-1) and Tenax TA (60/80 mesh, specific surface area of 35 m2·g-1 and a density of 127
0.25 g·mL-1) were used as sorbent materials (Supelco, Bellefonte, PA, USA). Reagents 128
(purity >97%, Table 1) were supplied by Sigma-Aldrich (Steinheim, Germany).129
22-gauge (22G, O.D. 0.71 mm, I.D. 0.41 mm, 51 mm length) stainless steel (metal hub) 130
needles with point style 5 were from Hamilton (Bonaduz, Switzerland). Gold wire of 131
100 m diameter (Supelco) was used to prepare the spiral plugs and hold sorbent 132
particles inside the needles. 20 mL crimp-cap HS vials, Teflon/silicone septum and caps 133
were purchased from Fisher Scientific Spain (Madrid).134
Stock solutions were freshly prepared daily by spiking milli-Q water (Millipore Iberica, 135
Barcelona, Spain) with 50 L of a methanolic solution containing the compounds at 136
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320-590 mg·L-1. These solutions were transferred to HS vials, filling them to avoid any 137
remaining headspace. The vials were then closed and stored at 4ºC. Working solutions 138
were prepared by the appropriate dilution of the stock solution in milli-Q water. In order 139
to prevent VOC losses during the preparation of the solutions and samples, glass 140
syringes (Hamilton) were used for sample transfer avoiding the formation of any gas 141
space in the syringe [38].142
143
2.2. Sampling by needle-trap device144
Each NTD was prepared by taking a 51-mm long, 22G, stainless steel needle and filling 145
it with the sorbent materials The protocol used to immobilize sorbent particles inside the 146
needle has been previously described [37,39]. Each NTD was conditioned in the GC 147
injector at 300ºC for 2-3 hours with a permanent helium flow to remove impurities. 148
Finally, the tip end was sealed with the help of a Teflon septum and the upper part of 149
the needle was closed with a push-button syringe valve (SGE Europe Ltd, Milton 150
Keynes, UK) to prevent contamination during storage.151
Sample extraction was performed with a bi-directional syringe pump (New Era Pump 152
System Inc., Farmingdale, NY, USA). The pump was programed to complete 1 mL 153
sampling cycles at 2 mL·min-1. The air drawn from the vial was injected back through154
the NTD at 2 mL·min-1 to maintain the pressure conditions inside the vial.155
Desorption and transfer of VOCs into the GC column was performed taking advantage 156
of the desorptive flow produced by the internal air expansion inside the needle at the hot 157
desorption temperatures of the GC injector [39]. The NTD was inserted into the 158
injection port in the splitless mode for one minute. After opening the split valve, the 159
needle was kept in the hot injector for one minute. Blank runs were carried out every 160
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five samples, analyzing the NTD just after a desorption step and before sampling again,161
and no carry over was observed.162
163
2.3 GC-MS analysis164
Component separation was achieved by the use of a 30 m long TR-Meta.VOC column 165
with 0.25 mm I.D. and 1.5 m film thickness (Teknokroma, Barcelona, Spain). A Focus 166
GC (Thermo Scientific, Waltham, MA, USA) with a mass spectrometer detector (DSQ 167
II, Thermo Scientific) was used.168
The injector (desorption) temperature was maintained at 300ºC to ensure complete and 169
fast desorption of target VOCs [39-41]. The oven temperature program was 40ºC for 4170
min, then ramped at 5ºC·min-1 to 150ºC, followed by a ramp at 10ºC·min-1 to 225ºC and 171
held for 2 min. Helium carrier gas was used with a constant inlet flow of 0.8 mL·min-1172
after purification for water vapor, hydrocarbons and oxygen. MS analyses were carried 173
out in full-scan mode, with a scan range of 40-250 uma, electron impact ionization was 174
applied at 70 eV, and the transfer line was maintained at 230ºC. Chromatographic data 175
was acquired by means of Xcalibur software (v. 1.4, Thermo Electron).176
177
2.4. Blood samples178
Whole blood samples were collected by venipuncture into vacutainers containing EDTA 179
as the anticoagulant (BD Vacutainer, Trenton, NJ, USA). Whole blood samples were 180
refrigerated at 4ºC within 10 minutes [8,15,32]. Freezing blood samples is not 181
recommended as it lyses the red cells and may change the equilibrium within the matrix 182
[15,32]. All measurements were performed within 14 days of collection [8,32].183
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For the VOC measurements, 0.5 mL blood was mixed with 2.0 mL water and 0.4 g 184
NaCl (i.e., 0.16 g·mL-1 salt content) in the HS vials. Vials were first incubated for 5 185
minutes in a dry bath at 30ºC (Model FB15101, Fisher Scientific, Loughborough, UK).186
Afterwards, 20 cycles (a total volume of 20 mL) were programed to collect the VOCs 187
on the sorbents. All samples were determined three times.188
189
2.6. Experimental design and statistical analysis190
A full factorial design was performed to evaluate the influence of the parameters on the 191
extraction of VOCs from blood samples with the NTDs. This allowed us to determine 192
the influence of the experimental variables studied and also to ascertain the interactions 193
between them. For each analyte, we considered two variable factors that can affect the 194
extraction yield: volume of gas sample passed through the NTD quantified as the 195
number of cycles (n) and the equilibration time before starting the sorption process (t). 196
We then selected a 22 full factorial design. Table 2 shows the experimental range for 197
each factor. The central point (10 cycles, 25 min) was also measured and considered as 198
an experiment. All experiments were duplicated randomly, except for the central point 199
that was triplicated. Minitab v14 software was used for data manipulation and 200
calculations [42]. SPSS for Windows (v. 15.0) was used for other statistical analyses. 201
202
3. Results and discussion203
3.1. Sampling methodology204
The evaluation of different HS sampling methodologies with NTDs [37] showed that 205
this methodology can reach limits of detection (LODs) at the ng·L-1 level. A dynamic 206
sampling procedure was applied in the present study. Eom et al. [43] compared three 207
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syringe pump assisted dynamic HS procedures for collecting a fixed volume of 208
headspace sample. They found that using various sorption cycles and returning the 209
extracted gas volume to the vial after each cycle resulted in a significant improvement 210
in the sensitivity compared to a conventional purge-and-trap method. They suggest that 211
the increase in the amount extracted was due to the minimum dilution effect resulting 212
from recycling the air. Therefore, a similar recycling system was used in the present 213
study. Instead of returning the filtered air through a separate channel, our system 214
recycles it back through the sorbent bed, eliminating the need for a distribution valve so 215
simplifying the instrumentation required. The binding of the analytes to the bed is 216
sufficiently strong as to avoid any analyte loss when recycling a small volume of gas 217
through it [44].218
The percentage of analyte trapped in each cycle can be determined by a simple 219
preliminary calculation. If a 15 mL HS volume (VHS) is used and each cycle collects 1220
mL (Vc) of this volume through the trap, the amount of the analyte retained in each 221
cycle will be 6.7% of the VOC content present in the HS (assuming that all the VOCs 222
present in the volume passed through the trap are adsorbed):223
(eq. 1)
Therefore, it can be determined that the percentage of analyte remaining in the HS after 224
each cycle (Ci,HS) is:225
(eq. 2)
and the percentage of analyte retained by the sorbent trap (Ci,T) after each cycle is:226
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(eq. 3)
In these conditions, 34 cycles will be required to transfer 90% of the analytes in the HS 227
to the trap (Figure 1). A preliminary study was performed to determine the percentage 228
of compound extracted at different numbers of cycles for the target compounds 229
evaluated. As can be seen in Figure 1, the experimental retention percentages found for 230
all VOCs fitted with the proposed model, which confirms that no-breakthrough took 231
place and that quantitative adsorption was obtained in each cycle.232
The sampling temperature also has a significant effect on the sorption mechanism of the 233
volatile compounds by NTDs [37,43]. Although an increase in the temperature increases 234
the partition of volatile compounds through the gas phase, breakthrough was observed 235
for benzene at sampling temperatures above 40ºC [43]. Increase in the headspace 236
temperature results in a competitive desorption of the most volatile compounds from the 237
sorbent, which is more important when a large volume of gas phase is transported 238
through the material [37]. Moreover, temperatures <47ºC are required when 239
determining VOCs from blood samples [16]. A temperature of 30±0.1 ºC was selected 240
for the measurements. The use of low temperatures reduces the formation of water 241
vapor in the gas phase, which would otherwise compete with the VOCs for the sorption 242
sites of the carbon molecular sieves (Carboxen 1000) [45].243
244
3.2. Study of the sampling conditions245
An experimental domain was defined to ascertain the influence of incubation time and 246
the number of cycles on the extraction of the target compounds from aqueous solutions 247
(Table 2). A full two-level factorial design was implemented to check for the presence 248
of interactions and evidence of curvature effects that could not be detected using a 249
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classical procedure based on the evaluation of each variable individually. Absolute peak250
areas were analyzed and the results obtained are summarized in Table 3 with p-values. 251
The sign next to each variable name indicates the optimal level to maximize the 252
response. The results obtained show that no statistically relevant interactions occurred 253
between the variables evaluated in any compound. The corresponding p-values for 254
single interactions are always much smaller than those for the double interaction, even 255
in the cases of 2,5-dimethylfuran, o-xylene and 1,2-dichlorobenzene, where the double 256
interactions are significant by themselves but are not when compared with the single 257
ones. In all the cases, the factor that clearly controls the process is the number of cycles 258
(see Supplementary Materials for the complete results). For a fixed number of cycles,259
factor time does not have a significant effect. Clearly relevant curvature effects were not 260
detected, except the small interaction found in Furan.261
Although 40 cycles are theoretically required to retain >90% of VOCs in the conditions 262
used (17.5 mL HS and 1 mL cycle), the number of cycles was fixed at 20 (expected 263
total extraction ~70%) and the incubation time chosen was 5 minutes to reduce the total 264
analysis time. In these conditions, a total sampling time of 25 minutes (5 min 265
incubation, and 30 seconds for sampling and 30 seconds for recycling in each cycle) is 266
required for each analysis. This allows sufficient time to condition the NTD and 267
perform a new sorption while a prior analysis is run.268
269
3.3. Salting-out effect270
As indicated in the introduction section, compensation of the salting-out effect is 271
necessary in biological fluids as the ionic strength of blood may vary considerably from 272
one sample to another [36]. Furthermore, the effect of the ionic-strength in fortified 273
blood samples was evaluated to determine whether adding a salt improves the extraction 274
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efficiency of the NTDs. Sodium chloride was added to the samples in order to obtain 275
0.16 g·mL-1 of salt content. The extraction efficiency of all compounds improved 276
significantly with the addition of salt (p<0.05, t-test, one-side), except for carbon 277
tetrachloride (p=0.167) (Figure 2). In the case of the two most polar compounds, ethyl 278
acetate was not detected and acetone was detected close to its detection limit without the 279
addition of salt, but they were both clearly detected once salt was added. Therefore, the 280
salting-out effect is required for the HS-NTD methodology to improve the sensitivity of 281
the method and to compensate the different ionic strengths of blood samples.282
283
3.4. Matrix effect284
The complexity of blood requires the evaluation of matrix effects. The use of external 285
calibration is the simplest and fastest quantification method. However, this can be286
strongly affected by matrix effects. This problem can often be overcome with complex 287
biological samples by diluting the sample.288
A pool of different blood samples was used as a matrix solution for recovery studies. 289
Recoveries were calculated by analyzing both the pooled blood sample, with the 290
dilution ratio required in each case, and the same sample fortified at a fixed mass for 291
each compound. The recovery percentage was determined as the ratio between the 292
calculated mass difference obtained and the spiked mass in the fortified sample.293
Figure 3 shows the recoveries obtained with different diluting rates. There are strong 294
interactions between the target compounds and the matrix components as none of the 295
compounds evaluated yielded quantitative recoveries without dilution of the blood 296
sample or with a 1:1 (blood:water) dilution. The results indicate that the greater the 297
volatility of the compound, the lower the interaction with the matrix. Most volatile 298
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compounds evaluated (furan, carbon tetrachloride and benzene) yielded quantitative 299
recoveries with a 1:2 dilution. Intermediate volatiles (2,5-dimethylfuran, 1,2-300
dichloropropane and toluene) gave reasonable recoveries (>75%) with a 1:3 dilution. 301
Other less volatile compounds (ethylbenzene, xylenes and styrene) required a 1:4 302
dilution to obtain good recoveries. The least volatile compound evaluated (1,2-303
dichlorobenzene) did not yield adequate recoveries in any of the dilutions. The tendency 304
observed suggests that this compound suffers a strong matrix effect that cannot be 305
solved simply by dilution. Therefore, 1:4 dilution is required to analyze target VOCs, 306
except 1,2-dichlorobenzene. The use of blood dilution has the disadvantage of 307
increasing the detection limits of VOCs in blood.308
309
3.4. Figures of merit of the HS-NTD methodology310
Calibration standard mixtures (n=6, each measured twice) in the 0.2 to 50 g·L-1 range311
for each compound were analyzed (corresponding to concentrations in the undiluted 312
blood samples in the 1 to 250 g·L-1 range). Acetone, hexane, ethyl acetate, chloroform,313
and carbon tetrachloride were excluded from the calibrations due to blank 314
contamination as they are solvents that are commonly used in adjacent laboratories.315
Table 4 shows the figure of merits obtained in these experiments. LODs were calculated 316
by analyzing a standard at 0.05-0.1 g·L-1 (n=5) with the SD obtained being taken as the 317
SD of the blank [46,47]. The 3SDblank criterion was then applied to calculate LODs. 318
Positive detection was confirmed by preparing standards and fortified blood samples at 319
the calculated values and then measuring them with the HS-NTD method. When the 320
conventional signal-to-noise ratio (S/N=3) was used, the LODs obtained were one order 321
of magnitude lower than those of the first option (ranging from 0.003 to 0.018 g·L-1). 322
Page 17 of 38
Ac
ce
pte
d M
an
us
cri
pt
16
However, these values only correspond to the instrumental detection limit and do not 323
take into account blank contaminants, which are a ubiquitous problem with some 324
compounds at ng·L-1 level (see Figure S1 in Supplementary Materials). We decided to325
use the first method as it takes into account blank contamination and repeatability at low 326
concentrations. Blank analyses always gave values below LODs when this procedure 327
was applied.328
Limit of quantification (LOQ) values in Table 4 correspond to the first calibration 329
standard used that gave a signal >10SDblank [46,47]. Linearity was confirmed in the 330
range of LOQ to 50 g·L-1 by evaluating residual distribution. Good fits were achieved 331
for all compounds (R2>0.983, except for styrene).332
Recoveries were evaluated from blood samples fortified at the levels indicated in Table 333
5. The results obtained were adequate for all compounds, except for 334
1,2-dichlorobenzene, which yielded a 30% recovery. Precision (repeatability) was 335
determined at high and LOQ levels. All compounds gave repeatability values within the 336
precision limits suggested by the ICH (precision not to exceed 15% except for the LOQ337
level, where it should not exceed 20%) [46,47].338
The trueness of the achieved results was determined by evaluating five blood samples in339
triplicate with the proposed NTD methodology and a conventional SPME method to 340
analyze VOCs in blood. The same compounds were identified in each sample for both 341
methods. A paired t-test was performed for those compounds giving concentration 342
values above LOQs and no significant differences were obtained in any of the 343
comparisons (p>0.1).344
The large phase ratio (=7) used in this study is a disadvantage for the detection of most 345
volatile compounds as their concentrations in the gas phase are reduced due to the large 346
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volume in this phase. Some experiments were performed using a higher volume of 347
sample (Vs=10 mL, =1.0). In these conditions, the percentage of extraction is expected 348
to increase from ~69% to ~88% (calculated from eq. 1, 2 and 3). The results obtained 349
confirmed a significant increase in the extraction efficiency of the NTDs (slope in the 350
calibration curves increased by a factor of between 1.4 and 2.1). An improvement in the 351
precision and the detection limits were also observed (Table S1 in Supplementary 352
Materials).353
Two IS were evaluated (d-furan and d-benzene) to see whether the precision and 354
calibration response could be improved. Determination coefficients in the calibration 355
curves measured for the two phase ratios indicated previously (=7 and =1) showed a 356
significant improvement for the most volatile compound (furan) when d-furan was used 357
as the IS (R2 increased from 0.985 to 0.994 with a =7 and from 0.968 to 0.995 with a 358
=1). No other compound showed any improvement with any of the IS evaluated. This 359
seems to indicate that the use of an IS with NTDs is important for the most volatile 360
compounds. It should be noted that only the target VOC that cannot be quantitatively 361
retained by the hydrophobic Tenax TA sorbent (furan), and which we would expect to 362
be retained by the stronger sorbent (Carboxen 1000, a carbon molecular sieve), showed 363
an improvement in the results with the use of an IS. This effect could be attributed to 364
the fact that the distance that this compound has to travel inside the NTD after thermal 365
desorption is relatively large, and so there may be a less reproducible desorption process 366
and slow transport to the GC column. The use of an IS with the same 367
sorption/desorption characteristics seems to be useful in avoiding these reproducibility 368
problems.369
370
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3.5. Analysis of blood samples371
Twenty-eight samples from different individuals (12 non-smokers, 7 ex-smokers and 9 372
smokers) were evaluated with the developed HS-NTD methodology. The method with 373
the lower phase ratio (=7) was chosen for the analysis of samples as there were some 374
difficulties in obtaining large volumes of blood from some of the volunteers. Figure 4375
shows the chromatogram obtained for a sample from a smoker.376
Three of the target compounds (furan, 2,5-dimethylfuran and 1,2-dichloropropane) were 377
not detected in any of the samples. In the case of benzene, two samples gave outlying378
results and were excluded from the analysis. This compound was detected in 17 samples 379
(65.4%). Toluene was detected in all samples (100%). Ethylbenzene was detected in 15 380
samples (53.6%). p-xylene was detected in 19 samples (68%). o-xylene was detected in 381
7 samples (25.0%). Styrene was detected in 21 samples (75.0%). Ethylbenzene, 382
o-xylene and styrene were always detected below LOQs. Table 6 shows the summary of 383
the results obtained together with those obtained in other studies where blood levels in 384
non-exposed individuals were evaluated [7-9,48-51]. As can be seen, the results agree 385
with those found in previous studies.386
Despite the limited number of samples, a preliminary statistical evaluation of the data 387
was performed to evaluate the possible existence of differences between smokers, 388
former smokers and non-smokers. For statistical analysis, a value of (LOD/ ) was 389
used in the case of non-detected compounds. Benzene was the only compound that gave 390
significant differences between the three sub-groups evaluated (p=0.005, ANOVA test, 391
Figure 5). All other target compounds gave non-significant differences (p>0.05). In the 392
case of benzene, the use of a post-hoc test (Tukey B) showed that the smokers group 393
gave significantly higher levels than non-smokers (p=0.005) and ex-smokers (p=0.030), 394
and that these two non-smoking groups did not differ between them (p=0.888).395
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4. Conclusions397
The NTD methodology has been evaluated for its use in the analysis of VOCs from 398
blood samples of unexposed individuals. The complexity of blood samples results in a 399
significant matrix effect that can be eliminated by the dilution of the blood samples, 400
although this leads to an increase in the detection limits. The LODs obtained in the 401
conditions evaluated are relatively large for an adequate quantification of VOCs in 402
unexposed individuals. This problem can be overcome by decreasing the phase ratio 403
during the HS process (i.e., increasing the volume of the sample) or by increasing the 404
number of cycles for the sorption process. The results obtained show that the HS-NTD 405
technique is a good alternative to conventional SPME methods for the analysis of VOCs406
in complex biological matrices. It can be easily automated and it is very robust. More 407
than 200 consecutive analyses have been performed with the same needle trap without 408
any significant variation in the precision and sensitivity.409
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501
Figure Captions502
Figure 1. Increase in the sorption of VOCs with the number of cycles (1 mL HS 503
sampling each cycle) using the proposed dynamic HS-NTD system (calculated from eq. 504
3). Experimental values obtained for furan (), benzene () and toluene (). Model 505
evaluated for a phase ratio =3 (5 mL sample and 15 mL HS). Three replicates for each 506
value.507
Figure 2. Salting-out effect on the adsorption of VOCs with the dynamic HS-NTD 508
system. Black blocks without the addition of salt, white blocks with an 0.16 g·mL-1509
NaCl content. Three replicates each.510
Figure 3. Recoveries obtained without blood dilution and different blood:water dilution 511
ratios to assess matrix effects. Pooled blood sample fortified in the range 15-20 g·L-1512
range for each VOC, =7, 0.16 g·mL-1 NaCl, 20 cycles. Three replicates each.513
Figure 4. Extracted chromatogram (m/z= 57,63,68,71,78,83,91,96,104,106,117,146) 514
obtained in the analysis of a blood sample from a smoker. Numbers by peaks 515
correspond to the compound numbers in Table 1.516
Figure 5. Box plots of data obtained for benzene. The bottom and top of the box are 517
25th and 75th percentiles, the line inside the box is the median (50th percentile), and the 518
whiskers indicate the lowest and highest data within the 1.5 interquartile range.519
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520
Table 1. List of volatile compounds evaluated521
# Compound name Retention time (min) Characteristic masses a
1 Furan 4.1 68
2 Acetone 4.2 43,58
3 Hexane 7.4 57,69,85
4 Ethyl acetate 8.0 43,71,86
5 Chloroform 8.2 83,85
6 Carbon tetrachloride 9.6 117,119
7 Benzene 10.0 77,78
8 2,5-dimethylfuran 11.5 81,95,96
9 1,2-dichloropropane 11.8 63,112
10 Toluene 14.4 91,92
11 Ethylbenzene 18.4 91,106
12 m-, p-xylene 18.6 91,105,106
13 o-xylene 19.8 91,105,106
14 Styrene 19.9 78,104
15 1,2-dichlorobenzene 25.9 111, 146, 148
a Quantification masses in bold522
523
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523
Table 2. Factor levels considered in optimizing the experimental design.524
Variable Low level (-) Medium level (0) High level (+)
Number of cycles (n) 1 10 20
Equilibration time (t, min) 5 25 45
525
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Table 3.  Statistical results for the experimental design. Significance p-values are given for main effects, double interactions and for curvature 526
evidence. Relevant single and double variable terms effects are also shown (the signs indicate the optimal variable level). When the double 527
interaction is relevant, the p-values attached to each single interaction are also given.528
529
530
531
532
533
534
535
536
Single variable effects Double variable effects
Compound
p-value 
Most significant
terms (p-value)
p-value 
Significant 
terms
p-value for 
curvature 
evidence
Furan <0.001 +n 0.102 0.024
Carbon tetrachloride 0.008 +n 0.895 0.354
Benzene 0.001 +n 0.895 0.400
2,5-dimethylfuran <0.001 +n(<0.001)  +t(<0.001) 0.001 +nt 0.509
1,2-dichloropropane <0.001 +n 0.305 0.508
Toluene <0.001 +n 0.452 0.654
Ethylbenzene <0.001 +n 0.346 0.887
m-, p-xylene <0.001 +n 0.241 0.943
o-xylene <0.001 +n(<0.001)  +t(0.019) 0.044 +nt 0.292
Styrene <0.001 +n 0.252 0.716
1,2-dichlorobenzene <0.001 +n(<0.001)  +t(0.007) 0.021 +nt 0.832
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Table 4. Linearity parameters, determination coefficients (R2) and limits of detection 537
(LOD) and quantification (LOQ) for the target VOC with the HS-NTD methodology538
(method with =7).539
a Limit values in undiluted blood samples are given between brackets 540
541
Compound slope (SD) R2 LOD a LOQ a
(·104) (g·L-1) (g·L-1)
Furan 194 (8) 0.985 0.04 (0.2) 0.20 (1.0)
Benzene 1067 (33) 0.995 0.08 (0.4) 0.24 (1.2)
2,5-dimethylfuran 448 (27) 0.983 0.02 (0.1) 0.28 (1.4)
1,2-dichloropropane 223 (12) 0.987 0.04 (0.2) 0.36 (1.8)
Toluene 1519 (79) 0.987 0.04 (0.2) 0.28 (1.4)
Ethylbenzene 1528 (113) 0.989 0.04 (0.2) 0.28 (1.4)
m-, p-xylene 525 (36) 0.987 0.06 (0.3) 0.26 (1.3)
o-xylene 637 (28) 0.991 0.04 (0.2) 0.26 (1.3)
Styrene 589 (47) 0.970 0.02 (0.1) 0.28 (1.4)
1,2-dichlorobenzene 541 (42) 0.990 0.05 (0.25) 0.28 (1.4)
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Table 5. Recoveries and repeatability obtained with the HS-NTD methodology proposed.542
543
544
545
546
547
548
549
550
551
552
553
a repeatability obtained with a spiked sample at a concentration equal to the value indicated in the “fortified level” column554
b range of repeatabilities obtained in the measure of blood samples. Mean RSD obtained from all quantified blood samples is indicated between 555
brackets 556
c Measured in five consecutive days557
Fortified
level
Recovery (SD) Repeatability (RSD, %) (n=5) Reproducibilityc (RSD, %) (n=5)
Compound
(g·L-1) (%) (n=3) high levela LOQ level blood samplesb high levela
Furan 15 99 (9) 7 15 ND 13
Benzene 14 117 (9) 10 14 4-22 (15) 15
2,5-dimethylfuran 14 109 (12) 9 18 ND 14
1,2-dichloropropane 18 115 (14) 10 21 ND 17
Toluene 14 109 (15) 12 12 4-20 (11) 18
Ethylbenzene 14 97 (13) 11 23 <LOQ 17
m-, p-xylene 14 93 (12) 9 20 6-23 (14) 15
o-xylene 14 90 (11) 10 22 <LOQ 16
Styrene 14 75 (8) 12 11 <LOQ 18
1,2-dichlorobenzene 21 29 (2) 8 20 ND 16
Page 32 of 38
Ac
ce
pte
d M
an
us
cri
pt
31
Table 6. Main statistical parameters of blood concentrations of target VOCs (g·L-1). 558
Mean Median Minimum Maximum n LOD Reference
benzene
<LOQ <LOQ ND 2.610 26 0.400 This study
0.176 0.102 0.032 0.728 287 0.024 7
0.072 -- -- -- 12 0.032 8
0.262 0.194 ND 2.241 431 0.015 9
0.094 0.062 0.033 0.487 61 0.016 48
0.226 0.106 0.046 1.187 25 0.016 49
-- 0.062 -- 1.880 796 0.030 50
-- <LOQ -- 0.480/0.320 837/1345 0.024 51
2,5-dimethylfuran
ND ND ND ND 28 100 This study
0.029 0.002 -- 0.373 61 -- 48
-- ND -- 180 1221 12 51
toluene
1.543 1.150 <LOQ 3.100 28 0.200 This study
0.442 0.234 ND 4.880 292 0.025 7
1.200 -- -- -- 13 0.088 8
1.100 0.559 0.120 6.040 25 0.043 49
-- 0.281 -- 6.767 575 0.092 50
-- 0.160/0.096 -- 1.430/0.880 954/1336 0.025 51
ethylbenzene
<LOQ <LOQ ND 0.690 28 0.200 This study
<LOQ <LOQ ND 0.949 251 0.024 7
0.120 -- -- -- 13 0.012 8
0.231 0.145 ND 0.596 25 0.022 49
-- <LOQ -- 3.731 606 0.020 50
-- <LOQ -- 0.180/0.120 879/1299 0.024 51
m-, p-xylene
<LOQ <LOQ ND 1.750 28 0.300 This study
0.261 0.174 ND 5.300 285 0.034 7
0.540 -- -- -- 13 0.010 8
0.719 0.457 <LOQ 1.713 25 0.052 49
-- 0.117 -- 33.057 1018 0.033 50
-- 0.150/0.130 -- 0.890/0.400 962/1346 0.034 51
o-xylene
<LOQ ND ND <LOQ 28 0.200 This study
<LOQ <LOQ ND 2.260 298 0.024 7
0.350 -- -- -- 13 0.024 8
-- 0.101 -- 3.487 628 0.040 50
-- ND -- 0.180/<LOQ 981/1365 0.049 51
styrene
<LOQ <LOQ ND 0.600 28 0.100 This study
0.050 -- -- -- 13 0.010 8
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-- <LOQ -- 4.006 624 0.019 50
-- ND -- 0.260/0.130 950/1245 0.030 51
559
ND: <LOD560
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